Lundbeck Wins FDA Fast Track for Lu AH69593 in Narcolepsy
VALBY, Denmark, July 23, 2026 Lundbeck has received U.S. Food and Drug Administration (FDA) Fast Track designation for Lu...
cardiovascular disease
Advertisement
Royalty Pharma Acquires Cliramitug Royalty Rights from Neurimmune
NEW YORK, July 22, 2026 Royalty Pharma plc has announced the acquisition of a portion of Neurimmune’s royalty interest...
Arrowhead Pharmaceuticals Reports Positive Phase 3 Plozasiran Results
PASADENA, Calif., July 22, 2026 Arrowhead Pharmaceuticals announced positive topline results from its pivotal Phase 3 SHASTA-3 and SHASTA-4...
Argo Biopharma Doses First Patient in BW-41012 Trial
SHANGHAI, China & NEW YORK, July 20, 2026 Argo Biopharma has announced the successful dosing of the first participant...
Cardiol Therapeutics Publishes Recurrent Pericarditis Phase II Data
TORONTO, Ontario, July 14, 2026 Cardiol Therapeutics Inc. has announced the publication of its Phase II MAvERIC clinical trial...
Advertisements
AstraZeneca Reports Wainua Phase III ATTR-CM Trial Results
CAMBRIDGE, United Kingdom, July 9, 2026 AstraZeneca and Ionis Pharmaceuticals have announced results from the Phase III CARDIO-TTRansform trial...
NewAmsterdam Pharma to Present Obicetrapib Alzheimer’s Data
NAARDEN, the Netherlands & MIAMI, July 1, 2026 NewAmsterdam Pharma Company N.V. announced that it will present multiple clinical...
BridgeBio Reports Kidney Benefits With Attruby in ATTR-CM
PALO ALTO, Calif., July 2, 2026 BridgeBio Pharma, Inc. announced new post-hoc analyses published in Circulation: Heart Failure showing...
Apotex Secures Health Canada Approval for SEVMIA™
TORONTO, Ontario, June 30, 2026 Apotex Health Corp. announced that Health Canada has approved SEVMIA™ (semaglutide injection), making it...
Wave Life Sciences Initiates Phase 2a INLIGHT™ Trial of WVE-007 for Obesity and Cardiometabolic Diseases
CAMBRIDGE, Mass., June 24, 2026 Wave Life Sciences announced the initiation of the Phase 2a multidose portion of the...
Advertisement
